This site is intended for health professionals only
Our digital finance tool that allows you to compare your practice against others around the country, highlighting ways to maximise your practice income.
Gain access to a complete financial breakdown of your practice, learn from experts on how to maximise your QOF income and the best way to prioritise it, and stay up-to-date on the latest insights and advice related to improving your performance and profits.
Put together by the team behind Pulse, with the help of an expert advisory board, Pulse Live is the one-stop shop for GPs.
Join us to take part in a number of key debates, seminars, and workshops addressing the wider issues within healthcare provision, as well as interviews with senior figures from the NHS, Government and other healthcare bodies.
Content funded and provided by GSK
For healthcare professionals only
Prescribing information is available via a link at the bottom of the page
NICE updated its COPD guideline (in Dec 2018) to recommend a LAMA/LABA as initial maintenance therapy in patients with no asthmatic features/features suggesting steroid responsiveness who remain breathless/have exacerbations despite short acting bronchodilator therapy.1
According to the guidance, such patients should have spirometrically confirmed COPD as well as have been offered/received treatment for tobacco dependence (if smokers), had optimised non-pharmacological management and received relevant vaccinations.1
The NICE guidelines state that 'the evidence showed that, compared with other dual therapy combinations and monotherapy, LAMA+LABA':
© NICE 2019 Chronic obstructive pulmonary disease in over 16s: non-pharmacological management and use of inhaled therapies. Available from www.nice.org.uk/guidance/NG115 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. For more information on the NICE COPD guidelines see www.nice.org.uk/guidance/NG115.
GSK organised and funded a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA initial maintenance therapy (IMT) in COPD. Attendees were paid an honorarium for their time by GSK. Watch the video to understand why you might want to consider LAMA/LABA IMT in specific COPD patients.
There are many LAMA/LABAs to consider using as initial maintenance therapy, but not all are the same.
Anoro ▼ Ellipta (umeclidinium/vilanterol) is the only LAMA/LABA with head-to-head data vs tiotropium HandiHaler (LAMA) and vs Spiolto Respimat (LAMA/LABA).2-6
Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
PM-GB-UCV-WCNT-200007 | June 2020
© 2020 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.